Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...
We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion ...
Johnson & Johnson MedTech has announced U.S. 510(k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH ...
Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...
Using Nvidia and GE Healthcare technology, the robotic surgery system is intended to help surgeons diagnose lung cancer ...
We recently published a list of Jim Cramer Discusses These 12 Stocks & Says Mag 7 Stocks Are A Thing Of The Past. In this ...
South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...
Have a look at top DJIA Stocks today. Learn about their price action, movement and how they will react to market today.
Reports Q4 revenue was $38K and $600K for the year ended December 3 compared to no revenue in the same periods in 2023. The increase in ...
We recently published a list of Jim Cramer Discusses These 12 Stocks & Says Mag 7 Stocks Are A Thing Of The Past.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results